# GLP-1 Medications Transform Weight Loss Market as Safety Concerns Emerge

# SEO-Friendly Podcast Episode Description ## Navigating Ozempic: FDA Approves First GLP-1 Weight Loss Pill - Foundayo vs. Wegovy Battle Begins Discover the latest breakthrough in weight loss medications as the FDA approves **Eli Lilly's Foundayo** (orforglipron), the first oral GLP-1 pill for obesity treatment. This episode of Navigating Ozempic covers the groundbreaking approval that's reshaping the $100 billion metabolic health market. **What You'll Learn:** - **Foundayo approval details**: The first daily pill alternative to weekly Ozempic and Wegovy injections - **Clinical results**: 12.4% average weight loss over 72 weeks - **Affordable pricing**: As low as $25/month with insurance, $149 self-pay - **Market competition**: Eli Lilly vs. Novo Nordisk in the GLP-1 obesity drug wars - **Important safety updates**: Latest FDA warnings on gastroparesis, kidney injury, and pancreatitis - **Lawsuit information**: 2,914 active cases against GLP-1 manufacturers - **Good news**: FDA removes suicidal ideation warnings after comprehensive review - **Women's health concerns**: Muscle loss risks and metabolic implications - **Cardiovascular benefits**: New Health Canada approval for heart disease protection **Keywords**: Ozempic, Foundayo, orforglipron, Wegovy, GLP-1 medications, weight loss pills, semaglutide, obesity treatment, metabolic health, FDA approval, Eli Lilly, Novo Nordisk Perfect for anyone considering GLP-1 medications, healthcare professionals, or those tracking pharmaceutical industry developments. *A Quiet Please Production* Some great Deals https://amzn.to/49SJ3Qs For more check out http://www.quietplease.ai This content was created in partnership and with the help of Artificial Intelligence AI.